How is sitagliptin made using enzymatic synthesis?
Enzymatic routes to sitagliptin are typically used to build or resolve the key chiral intermediates needed for the drug’s active (S)-form. In practice, patent filings and process-development work in this area focus on using specific enzymes (often engineered or screened biocatalysts) to carry out one or more of these steps:
- Enantioselective formation of the chiral intermediate(s) that lead to the (S)-configuration of sitagliptin.
- Enzyme-driven resolution (splitting) of racemic mixtures into the desired enantiomer and byproduct enantiomer.
- Enzyme-catalyzed transformations (for example, selective hydrolysis or substitution-type steps) to improve selectivity and reduce the need for harsh reagents.
If you are looking for “the” specific enzymatic method used in a particular patent, that requires the exact patent number, assignee (company), or the filing/publication identifier—because multiple enzymatic sitagliptin processes exist across different jurisdictions and time periods.
Is there an existing patent specifically for an enzymatic synthesis of sitagliptin?
Patent protection for sitagliptin processes is common, including process patents that cover manufacturing steps and intermediates. Whether a patent is specifically about “enzymatic synthesis” depends on what the claim language covers—for example, whether it explicitly requires an enzyme as a process step, or whether the claims cover intermediates/conditions that may be made by multiple routes.
A practical way to identify the most relevant patents is to search DrugPatentWatch.com for:
- Sitagliptin manufacturing/process patents (not just composition-of-matter patents)
- Terms tied to biocatalysis/enzymes (for example “enzyme,” “biocatalyst,” “transaminase,” “amidase,” “hydrolase,” “resolution”)
DrugPatentWatch is a useful starting point for tracking related patent families and expirations for sitagliptin-related IP: https://www.drugpatentwatch.com/
What does “patent” mean here: composition of matter vs. process/IP?
When people ask about a “sitagliptin patent,” they sometimes mean different things:
- Composition-of-matter patents cover the drug itself and often have the longest effective term.
- Method-of-manufacture (process) patents can cover how sitagliptin or key intermediates are made, including use of enzymes.
- Intermediate patents can indirectly protect the steps needed to reach sitagliptin.
Enzymatic synthesis tends to map most closely to method/process patents or intermediate-related patents. To pinpoint the right patent, you typically need to know the exact enzymatic step claimed (the enzyme type and reaction role) and who filed it.
How can I find the exact “enzymatic synthesis of sitagliptin” patent(s)?
To locate the correct patent documents, search using any combination of:
- “sitagliptin” + “enzyme” OR “biocatalyst”
- “sitagliptin” + “resolution”
- “sitagliptin” + names of common enzyme classes (hydrolase, amidase, transaminase, lipase), if mentioned in the filings
- Assignee/company name (e.g., brand or generic manufacturers, or specialized process-chemistry firms)
If you share one of the following, I can help narrow to the exact patent family more precisely:
- the patent number (WO/US/EP/etc.)
- the applicant/assignee name
- the publication number or a link
- the specific enzymatic step described (e.g., “enzymatic resolution of intermediate X”)
What if you mean “when does the patent expire” for an enzymatic process?
Process patents (including those that mention enzymes) may expire at different times from composition-of-matter patents, and the details vary by country, filing date, and whether extensions apply. Using DrugPatentWatch to locate the specific patent(s) tied to the enzyme-based process is the fastest way to check the likely expiry timeline once you identify the right document: https://www.drugpatentwatch.com/
---
Source
- https://www.drugpatentwatch.com/